Hypertrophic Cardiomyopathy Clinical Trial
— VANISHOfficial title:
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Verified date | April 2020 |
Source | HealthCore-NERI |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and biochemistry.
Status | Completed |
Enrollment | 211 |
Est. completion date | July 2019 |
Est. primary completion date | July 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 45 Years |
Eligibility | Inclusion Criteria: 1. All subjects must have a Pathogenic or Likely Pathogenic HCM Sarcomere Mutation a. The following categories of mutations are considered acceptable for subjects who have previously undergone clinical genetic testing. If results are ambiguous, they will be reviewed by the Clinical Coordinating Center to determine eligibility. - Laboratory for Molecular Medicine (Pathogenic, Likely Pathogenic) - Transgenomics/ PGXHealth (Class I) - GeneDx (Disease causing; Variant; likely disease-causing; Published, disease-causing mutation; Novel, likely disease-causing, mutation) - Correlagen (Associated; Probably Associated) Group 1 (Overt HCM Cohort) 1. LV wall thickness =12 mm and =25 mm or z score =3 and =18 as determined by rapid assessment by the echocardiographic core laboratory 2. NYHA functional class I or II; no perceived or only slight limitations in physical activities 3. No resting or provokable LV obstruction (peak gradient = 30 mmHg) on clinically-obtained Exercise Tolerance Test (ETT)-echo within the past 24 months or transthoracic echo with Valsalva maneuver within the past 12 months 4. Age 8-45 years 5. Able to attend follow-up appointments, complete all study assessments, and provide written informed consent Group 2 (Preclinical HCM Cohort (G+/LVH-)) 1. LV Wall Thickness <12 mm and z score <3 , as determined by rapid assessment by the echocardiographic core laboratory 2. Age 10-25 years 3. E' z score = -1.5 OR ECG abnormalities other than NSSTW changes (Q waves, T wave inversion, repolarization changes) OR LV wall thickness z-score 1.5-2.9 combined with LV thickness to dimension ratio =0.19 (as determined by rapid assessment by the echocardiographic core laboratory) 4. Able to attend follow-up appointments, complete all study assessments, and provide written informed consent Subject Exclusion Criteria 1. Contraindication to angiotensin receptor blocker (ARB) administration, including impaired renal function, hyperkalemia (serum K>5.0 mmol/L), prior history of angioedema 2. Medical conditions associated with increased collagen turnover that may confound interpretation of biomarkers of collagen synthesis (liver, pulmonary or renal fibrosis, inflammatory states, cancer, trauma or surgery within 6 months of enrollment) 3. Concomitant use of Spironolactone, Lithium, or Aliskiren, ARB or ACE-inhibitors. If these drugs are in active use but not necessary for medical care, they may be discontinued and baseline studies can be performed after a 2-week washout period. 4. Pregnant or breastfeeding females - Females of childbearing potential with no effective contraceptive method (including abstinence) 5. Uncontrolled systemic HTN [persistent SBP>160 and/or DBP>90 in adult or equivalent in children (e.g., SBP>99th or DBP>95th percentile for sex, age, and height centile based on the American Academy of Pediatrics normal values)] 6. Obstructive physiology, defined by resting, Valsalva-provoked or exercise-induced gradient >30mmHg within the past 24 months 7. Prior septal myectomy or alcohol septal ablation 8. Known, suspected, or symptomatic coronary artery disease or evidence of prior myocardial infarction based on symptoms or cardiac imaging 9. More than mild valvular heart disease or clinically significant congenital heart disease. Allowable conditions include bicuspid aortic valve without clinically significant stenosis or regurgitation; spontaneously closed ventricular septal defects; patent foramen ovale, small (= 2 mm) restrictive ventricular septal defects with normal ventricular size, and other minor defects that are considered allowable after [review and consensus by participating pediatric cardiologists, overall study PI and] adjudication by the echocardiographic core laboratory. 10. Left ventricular ejection fraction (LVEF) <55% 11. Concomitant medical conditions that would preclude performance of or confound interpretation of echocardiography, exercise testing, or CMR (e.g., renal insufficiency, lung disease, orthopedic/rheumatologic conditions, atrial fibrillation) 12. Secondary prevention implantable cardioverter-defibrillator device (ICD; primary prevention ICDs without a history of appropriate therapy, including shock or ATP, are allowable). 13. Prior treatment or hospitalization for symptomatic heart failure 14. Participation in a clinical trial (except observational studies) involving investigational medications within the previous 30 days. |
Country | Name | City | State |
---|---|---|---|
Canada | Toronto General Hospital | Toronto | Ontario |
Canada | Toronto Sick Kids | Toronto | Ontario |
United States | University of Michigan | Ann Arbor | Michigan |
United States | University of Colorado | Aurora | Colorado |
United States | Johns Hopkins University | Baltimore | Maryland |
United States | Brigham & Women's Hospital | Boston | Massachusetts |
United States | Children's Hospital Boston | Boston | Massachusetts |
United States | University of Chicago | Chicago | Illinois |
United States | Cinncinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | Vanderbilt University | Nashville | Tennessee |
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Washington University School Medicine | Saint Louis | Missouri |
United States | Stanford University | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
HealthCore-NERI | National Heart, Lung, and Blood Institute (NHLBI) |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Safety of valsartan as assessed by incidence of adverse events | Safety of valsartan as assessed by incidence of adverse events | 2 years | |
Primary | Composite z-score | Composite z-score which is the average of 9 change-scores of: serum NTproBNP, serum high-sensitivity cardiac troponin, left ventricular (LV) mass, left atrial (LA) volume, LV end diastolic volume, LV end systolic volume, maximal LV wall thickness, echo E' velocity, echo S' velocity | 2 years | |
Secondary | z-score serum NTproBNP | Z-score for the 2 year change for serum NTproBNP | 2 years | |
Secondary | z-score high sensitivity cardiac troponin | Z-score for the 2 year change for high-sensitivity cardiac troponin | 2 years | |
Secondary | z-score LV mass | Z-score for the 2 year change in LV Mass | 2 years | |
Secondary | z-score LA volume | Z-score for the 2 year change in LA Volume | 2 years | |
Secondary | z-score LV end diastolic volume | Z-score for the 2 year change in LV end diastolic volume | 2 years | |
Secondary | z-score LV end systolic volume | Z-score for the 2 year change in LV end systolic volume | 2 years | |
Secondary | z-score maximal LV wall thickness | Z-score for the 2 year change in Maximal LV wall thickness | 2 years | |
Secondary | z-score echo E' velocity | Z-score for the 2 year change in echo E' velocity | 2 years | |
Secondary | z-score echo S' velocity | Z-score for the 2 year change in echo S' velocity | 2 years | |
Secondary | Binary indicator of success or failure | Success defined as an improvement at 2 years in any of the following: serum NTproBNP, serum high-sensitivity troponin, LV Mass, LA Volume, LV end diastolic volume, LV end systolic volume, Maximal LV wall thickness, echo E' velocity, or echo S' velocity | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03249272 -
Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
|
Phase 4 | |
Recruiting |
NCT03846297 -
Optimisation of Decision Making for Defibrillator Implantation in Hypertrophic Cardiomyopathy
|
||
Completed |
NCT02806479 -
Hypertrophic Cardiomyopathy Pilot Study
|
||
Active, not recruiting |
NCT01225978 -
Refining Information Technology Support for Genetics in Medicine
|
N/A | |
Completed |
NCT00001632 -
Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease
|
N/A | |
Completed |
NCT00001534 -
Long Term Effects of Enalapril and Losartan on Genetic Heart Disease
|
N/A | |
Enrolling by invitation |
NCT04050579 -
OPIE in the Thin Interventricular Septum
|
N/A | |
Completed |
NCT03537183 -
Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?
|
N/A | |
Completed |
NCT02590809 -
Hypertrophic Cardiomyopathy Symptom Release by BX1514M
|
Phase 2 | |
Completed |
NCT00001396 -
Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...
|
Phase 1 | |
Active, not recruiting |
NCT03723655 -
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
|
Phase 2/Phase 3 | |
Completed |
NCT05135871 -
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
|
Phase 1 | |
Completed |
NCT04129905 -
Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic Cardiomyopathies
|
N/A | |
Recruiting |
NCT03061994 -
Metabolomic Study of All-age Cardiomyopathy
|
N/A | |
Completed |
NCT02234336 -
Assessment of Wall Thickness in Hypertrophic Cardiomyopathy
|
||
Recruiting |
NCT00221832 -
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
|
N/A | |
Not yet recruiting |
NCT03706001 -
Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression
|
N/A | |
Recruiting |
NCT06169358 -
Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy
|
||
Not yet recruiting |
NCT04090437 -
HCM-AF Ablation With ACUTUS
|
N/A | |
Completed |
NCT04402268 -
Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy
|